Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: A prospective randomized trial from the lymphoma working party of the European Group for Blood and Marrow Transplantation

Journal of Clinical Oncology

Volumn 31, Issue 13, 2013, Pages 1624-1630

  Pettengell, Ruth ^a   Schmitz, Norbert ^e   Gisselbrecht, Christian ^h   Smith, Graeme ^d   Patton, William N ^j   Metzner, Bernd ^f   Caballero, Dolores ^k   Tilly, Herve ⁱ   Walewski, Jan A ^l   Bence Bruckler, Isabelle ^m   To, Bik ⁿ   Geisler, Christian H ^o   Schots, Rik ^p   Kimby, Eva ^q   Taverna, Christian J ^r   Kozák, Tomáš ^s   Dreger, Peter ^g   Uddin, Ruzena ^b   De Elvira, Carmen Ruiz ^b   Goldstone, Anthony H ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b European Group for Blood and Marrow Transplantation   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

^f KLINIKUM OLDENBURG   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j AUCKLAND CITY HOSPITAL   (New Zealand)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ ROYAL ADELAIDE HOSPITAL   (Australia)

^o International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^p UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^q KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^r KANTONSSPITAL   (Switzerland)

^s CHARLES UNIVERSITY   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FACTORIAL DESIGN; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SIDE EFFECT; SURGICAL MORTALITY; UNSPECIFIED SIDE EFFECT; AUTOTRANSPLANTATION; BONE MARROW PURGING; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECURRENT DISEASE; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BONE MARROW PURGING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84883265147     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.1862     Document Type: Article

References (30)

1. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005
2. van Oers MH, Tönnissen E, Van Glabbeke M, et al: BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: Results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 28:2853-2858, 2010
3. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
4. Pulte D, Gondos A, Brenner H: Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 168:469-476, 2008
5. Montoto S, Canals C, Rohatiner AZ, et al: Long-term follow-up of highdose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: An EBMT registry study. Leukemia 21:2324-2331, 2007
6. Rohatiner AZ, Nadler L, Davies AJ, et al: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 25:2554-2559, 2007
7. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
8. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003
9. van Oers MH, Klasa R, Marcus RE, et al: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial. Blood 108:3295-3301, 2006
10. Marcus R, Imrie K, Solal-Celigny P, et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579-4586, 2008
11. Salles G, Mounier N, de Guibert S, et al: Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Results of the GELA-GOELAMS FL2000 study. Blood 112:4824-4831, 2008
12. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomized controlled trial. Lancet 377:42-51, 2011
13. Le Gouill S, De Guibert S, Planche L, et al: Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 96:1128-1135, 2011
14. Forstpointner R, Unterhalt M, Dreyling M, et al: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108:4003-4008, 2006
15. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
16. Brugger W, Hirsch J, Grüneback F, et al: Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective multicenter Phase II study. Ann Oncol 15:1691-1698, 2004
17. Morschhauser F, Recher C, Milpied N, et al: A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: Results of a prospective multicenter phase II study of patients with follicular lymphoma. Ann Oncol 23:2687-2695, 2012
18. Hicks LK, Woods A, Buckstein R, et al: Rituximab purging and maintenance combined with auto-SCT: Long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 43:701-708, 2009
19. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
20. Sebban C, Brice P, Delarue R, et al: Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: A GELA study. J Clin Oncol 26:3614-3620, 2008
21. Tarella C, Zanni M, Magni M, et al: Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innnovative nei Linfomi survey. J Clin Oncol 26:3166-3175, 2008
22. Kornacker M, Stumm J, Pott C, et al: Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: A long-term follow-up. Ann Oncol 20:722-728, 2009
23. Vose JM, Bierman PJ, Loberiza FR, et al: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: Effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 14:36-42, 2008
24. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262, 1995
25. Al Khabori M, de Almeida JR, Guyatt GH, et al: Autologous stem cell transplantation in follicular lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 104:18-28, 2012
26. Cattaneo C, Spedini P, Casari S, et al: Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 47:1013-1017, 2006
27. Lim SH, Esler WV, Zhang Y, et al: B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 49:152-153, 2008
28. Shortt J, Spencer A: Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 38:433-436, 2006
29. Bhatia S, Ramsay NK, Steinbuch M, et al: Malignant neoplasms following bone marrow transplantation. Blood 87:3633-3639, 1996
30. André M, Henry-Amar M, Blaise D, et al: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92:1933-1940, 1998